Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

Crown Laboratories, Inc., a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc., a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, have amended and restated the merger agreement entered into by the parties on Aug. 11, 2024, with aim to merge the two organizations.

Under the terms of the amended and restated merger agreement, which has been unanimously approved by Revance’s Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $3.10 per share in cash.

“We are pleased to announce the terms of the amended and restated merger agreement, marking an important step forward towards the combination of our complementary organizations,” said Jeff Bedard, founder and CEO of Crown. “We believe Revance’s innovative aesthetics solutions will broaden Crown’s cutting-edge aesthetic offerings and, as a combined company, have the unique opportunity to build a comprehensive portfolio of high-growth products in aesthetics and consumer skincare that best serves our skin science for life vision.”

The transaction is expected to close in the first quarter of 2025. Following completion of the merger, Revance will be wholly owned by Crown and Revance’s stock will no longer be publicly traded on Nasdaq.